CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale Chief Medical Officer sold 1,654 shares at $22.29 ($36,868)
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 11,439 shares at an average $22.90 ($261,929)
- 4 Planned sale COFO and Secretary sold 2,768 shares at $23.44 ($64,882)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Gift President and CEO gave 32,220 shares (gift)
- 4 Open-market sale COFO and Secretary sold 2,857 shares at $25.07 ($71,625)
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Acquisition or sale completed
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Material agreement · Regulation FD disclosure
- 4 Grant or award Director acquired 6,408 shares (grant or award)
- 4 Grant or award Director acquired 6,408 shares (grant or award)
- 4 Grant or award Director acquired 6,408 shares (grant or award)
Page 1 of 40 · 789 filings